HCV Therapy in Decompensated Cirrhosis before or after Liver Transplantation: A Paradoxical Quandary.

about

HCV Therapy in Decompensated Cirrhosis before or after Liver Transplantation: A Paradoxical Quandary.

Item

http://www.wikidata.org/entity/Q50067192

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

HCV Therapy in Decompensated C ...... ation: A Paradoxical Quandary.

@en

HCV Therapy in Decompensated C ...... ation: A Paradoxical Quandary.

@nl

type

Item

label

HCV Therapy in Decompensated C ...... ation: A Paradoxical Quandary.

@en

HCV Therapy in Decompensated C ...... ation: A Paradoxical Quandary.

@nl

prefLabel

HCV Therapy in Decompensated C ...... ation: A Paradoxical Quandary.

@en

HCV Therapy in Decompensated C ...... ation: A Paradoxical Quandary.

@nl

P1476

HCV Therapy in Decompensated C ...... ation: A Paradoxical Quandary.

@en

P2093

Chalermrat Bunchorntavakul

http://www.w3.org/2001/XMLSchema#string

P2860

Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis.

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence

Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C.

Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy.

Optimum timing of treatment for hepatitis C infection relative to liver transplantation.

ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients.

Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study.

Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.

P31

scholarly article

P356

10.1038/AJG.2017.435

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

K. Rajender Reddy

P577

2017-12-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29206818

http://www.w3.org/2001/XMLSchema#string

P921

liver transplantation